ALPINE BIOSCIENCES

At Alpine Biosciences, our team is committed to developing therapies for cancer and rare diseases using our expertise in next-generation nanoparticles and drug development. Our team won approval of the world’s first cancer immunotherapy, igniting excitement for an entirely new anti-cancer market potentially worth over $30 billion in the coming decade.